Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 USD | +2.78% | -18.14% | +105.56% |
Apr. 15 | North American Morning Briefing : Stock Futures -2- | DJ |
Mar. 25 | BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment | MT |
Financials (USD)
Sales 2021 | 1.35 | Sales 2022 | 1.35 | Capitalization | 73.18M |
---|---|---|---|---|---|
Net income 2021 | -64M | Net income 2022 | -33M | EV / Sales 2021 | 80,326,725 x |
Net cash position 2021 | 68.79M | Net cash position 2022 | 32.31M | EV / Sales 2022 | 30,256,712 x |
P/E ratio 2021 |
-2.75
x | P/E ratio 2022 |
-2.21
x | Employees | 73 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 73.36% |
Latest transcript on BeyondSpring Inc.
1 day | +2.78% | ||
1 week | -18.14% | ||
Current month | -48.18% | ||
1 month | -35.76% | ||
3 months | +116.93% | ||
6 months | +79.61% | ||
Current year | +105.56% |
Managers | Title | Age | Since |
---|---|---|---|
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
G. Kenneth Lloyd
CTO | Chief Tech/Sci/R&D Officer | 80 | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Fabbio
BRD | Director/Board Member | 56 | 18-01-01 |
Lan Huang
CEO | Chief Executive Officer | 53 | 12-12-31 |
Matthew Kirkby
BRD | Director/Board Member | 55 | 16-10-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-16 | 1.8 | +2.27% | 37,542 |
24-04-15 | 1.76 | -15.79% | 75,265 |
24-04-12 | 2.09 | +1.46% | 46,767 |
24-04-11 | 2.06 | -8.85% | 130,211 |
24-04-10 | 2.26 | -5.83% | 150,073 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+105.56% | 70.23M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- BYSI Stock